Tempus AI, Inc. (NASDAQ: TEM) has entered a strategic collaboration with Daiichi Sankyo (OTCMKTS: DSNKY) to accelerate development of a new cancer therapy, using artificial intelligence to improve clinical trial outcomes.
The partnership focuses on advancing an antibody drug conjugate, or ADC, a targeted cancer treatment designed to deliver drugs directly to tumour cells. Additionally, Daiichi Sankyo will use Tempus’ AI platform to refine how patients are selected for trials. This approach aims to improve success rates and reduce costly late-stage failures.
Tempus will deploy its PRISM2 model, which analyzes both medical images and clinical data. Furthermore, the system integrates real-world patient data with trial and lab research. This combination allows researchers to identify patterns that traditional methods may miss.
The companies plan to build proof-of-concept models that predict how patients will respond to treatment. Meanwhile, they will apply these models across Tempus’ large oncology database. This process will generate response maps that show which patients benefit most from the therapy.
Additionally, the collaboration will support biomarker discovery, which helps identify measurable signs of disease or treatment response. In turn, this enables more precise patient stratification in clinical trials. Consequently, researchers can design studies with better-defined control groups and clearer outcomes.
A Tempus executive said the collaboration reflects a shift in how AI supports drug development. He explained that companies now use these tools not only for efficiency but also to design more targeted trials. Furthermore, he noted that multimodal AI can help uncover unmet patient needs and improve treatment matching.
Read more: Window-cleaning robot firm Lucid Bots raises USD$20M as demand accelerates
Read more: NEURA Robotics reportedly raising €$1B in round backed by crypto giant Tether
Artificial intelligence has opened new vistas for oncology
Tempus operates one of the largest libraries of clinical and molecular data in healthcare. Additionally, its platform allows physicians to access and apply this data in real time. The company aims to use AI to help doctors personalize treatment decisions for each patient.
Daiichi Sankyo continues to expand its oncology pipeline, with ADCs playing a central role. Meanwhile, this collaboration signals growing industry interest in combining AI with drug development.
This collaboration reflects a broader shift as artificial intelligence reshapes how cancer is detected, diagnosed, and treated.
Artificial intelligence is increasingly shaping oncology by improving how doctors detect, diagnose, and treat cancer. Additionally, AI systems can analyze imaging scans and pathology slides faster than traditional methods. This allows clinicians to identify tumours earlier, when treatment is often more effective.
Furthermore, AI can detect subtle patterns in medical data that human reviewers may miss. In turn, this supports more accurate diagnoses and reduces the risk of misclassification. Consequently, patients can receive treatments that better match their specific disease profiles.
Meanwhile, AI-powered tools are helping physicians predict how cancers will progress over time. These models combine genetic data, imaging, and clinical history to guide treatment decisions. Additionally, they can estimate how patients will respond to therapies before treatment begins.
Companies are rapidly integrating these capabilities into real-world products. Breath Diagnostics Inc is developing breath-based tests that use AI to identify cancer biomarkers from exhaled air.
Similarly, Guardant Health (NASDAQ: GH) applies AI to blood-based tests that detect cancer-related mutations without invasive procedures. Furthermore, these technologies can monitor disease progression in real time.
.
